Published in J Pharmacokinet Pharmacodyn on June 01, 2002
Arsenicals in maternal and fetal mouse tissues after gestational exposure to arsenite. Toxicology (2006) 1.08
Mathematical model insights into arsenic detoxification. Theor Biol Med Model (2011) 0.89
Mathematical modeling of the effects of glutathione on arsenic methylation. Theor Biol Med Model (2014) 0.81
A semi-mechanistic integrated toxicokinetic-toxicodynamic (TK/TD) model for arsenic(III) in hepatocytes. J Theor Biol (2012) 0.79
Mathematical model of uptake and metabolism of arsenic(III) in human hepatocytes - Incorporation of cellular antioxidant response and threshold-dependent behavior. BMC Syst Biol (2011) 0.78
A novel S-adenosyl-L-methionine:arsenic(III) methyltransferase from rat liver cytosol. J Biol Chem (2002) 2.85
Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp Biol Med (Maywood) (2007) 2.18
Elucidating the pathway for arsenic methylation. Toxicol Appl Pharmacol (2004) 2.09
Evaluation of the association between arsenic and diabetes: a National Toxicology Program workshop review. Environ Health Perspect (2012) 2.05
Inhibition of insulin-dependent glucose uptake by trivalent arsenicals: possible mechanism of arsenic-induced diabetes. Toxicol Appl Pharmacol (2004) 1.63
Molecular events associated with arsenic-induced malignant transformation of human prostatic epithelial cells: aberrant genomic DNA methylation and K-ras oncogene activation. Toxicol Appl Pharmacol (2005) 1.59
Endogenous reductants support the catalytic function of recombinant rat cyt19, an arsenic methyltransferase. Chem Res Toxicol (2004) 1.50
Disruption of the arsenic (+3 oxidation state) methyltransferase gene in the mouse alters the phenotype for methylation of arsenic and affects distribution and retention of orally administered arsenate. Chem Res Toxicol (2009) 1.41
Arsenic-induced malignant transformation of human keratinocytes: involvement of Nrf2. Free Radic Biol Med (2008) 1.39
Human health effects of trichloroethylene: key findings and scientific issues. Environ Health Perspect (2012) 1.34
Arsenic (+3 oxidation state) methyltransferase and the inorganic arsenic methylation phenotype. Toxicol Appl Pharmacol (2005) 1.20
Arsenic (+3 oxidation state) methyltransferase genotype affects steady-state distribution and clearance of arsenic in arsenate-treated mice. Toxicol Appl Pharmacol (2010) 1.10
Tissue dosimetry, metabolism and excretion of pentavalent and trivalent monomethylated arsenic in mice after oral administration. Toxicol Appl Pharmacol (2005) 1.09
Arsenicals in maternal and fetal mouse tissues after gestational exposure to arsenite. Toxicology (2006) 1.08
Selenium compounds modulate the activity of recombinant rat AsIII-methyltransferase and the methylation of arsenite by rat and human hepatocytes. Chem Res Toxicol (2003) 1.08
Methylarsonous acid transport by aquaglyceroporins. Environ Health Perspect (2006) 1.08
Gut microbiome perturbations induced by bacterial infection affect arsenic biotransformation. Chem Res Toxicol (2013) 1.04
Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach. Toxicol Appl Pharmacol (2009) 1.03
Accumulation and metabolism of arsenic in mice after repeated oral administration of arsenate. Toxicol Appl Pharmacol (2003) 1.00
Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res (2003) 0.99
Arsenite induces delayed mutagenesis and transformation in human osteosarcoma cells at extremely low concentrations. Environ Mol Mutagen (2003) 0.95
Development of a human physiologically based pharmacokinetic (PBPK) model for inorganic arsenic and its mono- and di-methylated metabolites. J Pharmacokinet Pharmacodyn (2007) 0.94
Difficulty of mode of action determination for trichloroethylene: An example of complex interactions of metabolites and other chemical exposures. Environ Mol Mutagen (2008) 0.93
Issues in the pharmacokinetics of trichloroethylene and its metabolites. Environ Health Perspect (2006) 0.93
Gut microbiome phenotypes driven by host genetics affect arsenic metabolism. Chem Res Toxicol (2014) 0.90
Glutathione-S-transferase pi inhibits As2O3-induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism. Blood (2004) 0.88
Prenatal arsenic exposure and shifts in the newborn proteome: interindividual differences in tumor necrosis factor (TNF)-responsive signaling. Toxicol Sci (2014) 0.87
Environmental arsenic as a disruptor of insulin signaling. Met Ions Biol Med (2008) 0.86
Genome-wide analysis of DNA methylation and gene expression changes in the mouse lung following subchronic arsenate exposure. Toxicol Sci (2010) 0.86
Tissue dosimetry, metabolism and excretion of pentavalent and trivalent dimethylated arsenic in mice after oral administration. Toxicol Appl Pharmacol (2007) 0.85
Research approaches to address uncertainties in the risk assessment of arsenic in drinking water. Toxicol Appl Pharmacol (2007) 0.83
Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report. Toxicol Appl Pharmacol (2007) 0.80
Analysis of arsenical metabolites in biological samples. Curr Protoc Toxicol (2009) 0.79
Kinetic modeling of beta-chloroprene metabolism: II. The application of physiologically based modeling for cancer dose response analysis. Toxicol Sci (2004) 0.78
A dosimetric analysis of the acute behavioral effects of inhaled toluene in rats. Toxicol Sci (2007) 0.78
Aging and susceptibility to toluene in rats: a pharmacokinetic, biomarker, and physiological approach. J Toxicol Environ Health A (2010) 0.78
Metabolism and mutagenicity of source water contaminants 1,3-dichloropropane and 2,2-dichloropropane. Drug Metab Dispos (2004) 0.78
Neurobehavioral effects of acute exposure to four solvents: meta-analyses. Toxicol Sci (2009) 0.77
A physiologically based pharmacokinetic model for intravenous and ingested dimethylarsinic acid in mice. Toxicol Sci (2008) 0.77
Genotoxicity and metabolism of the source-water contaminant 1,1-dichloropropene: activation by GSTT1-1 and structure-activity considerations. Mutat Res (2005) 0.77
Cutting Edge PBPK Models and Analyses: Providing the Basis for Future Modeling Efforts and Bridges to Emerging Toxicology Paradigms. J Toxicol (2012) 0.77
Acute toluene exposure and rat visual function in proportion to momentary brain concentration. Toxicol Sci (2007) 0.76
Scientific considerations for evaluating cancer bioassays conducted by the Ramazzini Institute. Environ Health Perspect (2013) 0.76
Quantitative comparisons of the acute neurotoxicity of toluene in rats and humans. Toxicol Sci (2007) 0.76
Acute perchloroethylene exposure alters rat visual-evoked potentials in relation to brain concentrations. Toxicol Sci (2008) 0.76
The metabolic rate constants and specific activity of human and rat hepatic cytochrome P-450 2E1 toward toluene and chloroform. J Toxicol Environ Health A (2004) 0.76
Moving from external exposure concentration to internal dose: duration extrapolation based on physiologically based pharmacokinetic derived estimates of internal dose. J Toxicol Environ Health A (2005) 0.76
Manipulation of expression of arsenic (+3 oxidation state) methyltransferase in cultured cells. Curr Protoc Toxicol (2010) 0.76
Purification of arsenic (+3 oxidation state) methyltransferase from rat liver cytosol. Curr Protoc Toxicol (2009) 0.75
Comments on article "Applying mode-of-action and pharmacokinetic considerations in contemporary cancer risk assessments: an example with trichloroethylene" by Clewell and Andersen. Crit Rev Toxicol (2006) 0.75
In vitro assays of inorganic arsenic methylation. Curr Protoc Toxicol (2009) 0.75
State of the science: biologically based modeling in risk assessment. J Toxicol (2012) 0.75
An example of model structure differences using sensitivity analyses in physiologically based pharmacokinetic models of trichloroethylene in humans. Bull Math Biol (2007) 0.75
Duration adjustment of acute exposure guideline level values for trichloroethylene using a physiologically-based pharmacokinetic model. Risk Anal (2005) 0.75
Visualization-based analysis for a mixed-inhibition binary PBPK model: determination of inhibition mechanism. J Pharmacokinet Pharmacodyn (2004) 0.75
A General Physiological and Toxicokinetic (GPAT) Model for Simulating Complex Toluene Exposure Scenarios in Humans. Toxicol Mech Methods (2006) 0.75
Preface: 2nd International Congress, As 2008: arsenic from nature to humans (Valencia, Spain, May 21-23). Environ Res (2010) 0.75